Effect of BG-12 (dimethyl fumarate) in newly diagnosed patients with relapsing-remitting multiple sclerosis from the DEFINE and CONFIRM studies

被引：0
|
作者：
Gold, R.
Giovannoni, G.
Phillips, J. T.
Fox, R. J.
Zhang, A.
Meltzer, L.
Kurukulasuriya, N. C.
机构：
[1] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany
[2] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England
[3] Baylor Inst Immunol Res, Multiple Sclerosis Program, Dallas, TX USA
[4] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44106 USA
[5] Biogen Idec Inc, Weston, MA USA
来源：
JOURNAL OF NEUROLOGY | 2013年 / 260卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O327
引用
收藏
页码：S51 / S51
页数：1
相关论文
共 50 条
  • [31] Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study
    Kita, Mariko
    Fox, Robert J.
    Phillips, J. Theodore
    Hutchinson, Michael
    Havrdova, Eva
    Sarda, Sujata P.
    Agarwal, Sonalee
    Kong, Jessica
    Zhang, Annie
    Viglietta, Vissia
    Sheikh, Sarah I.
    Seidman, Emily
    Dawson, Katherine T.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (02) : 253 - 257
  • [32] Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study
    Amit Bar-Or
    Ralf Gold
    Ludwig Kappos
    Douglas L. Arnold
    Gavin Giovannoni
    Krzysztof Selmaj
    John O’Gorman
    Monica Stephan
    Katherine T. Dawson
    Journal of Neurology, 2013, 260 : 2297 - 2305
  • [33] Clinical effects of BG-12 in subgroups of patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies
    Bar-Or, A.
    Fox, R. J.
    Gold, R.
    Giovannoni, G.
    Kita, M.
    O'Gorman, J.
    Yang, M.
    Sheikh, S. I.
    Viglietta, V.
    Dawson, K. T.
    Hutchinson, M.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 191 - 191
  • [34] Safety and Tolerability of BG-12 in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Analyses From the CONFIRM Study
    Phillips, J. Theodore
    Fox, Robert
    Miller, David
    Kita, Mariko
    Hutchinson, Michael
    Havrdova, Eva
    Raghupathi, Kartik
    Yuan, Huixing
    Novas, Mark
    Viglietta, Vissia
    Dawson, Katherine
    NEUROLOGY, 2012, 78
  • [35] Effects of BG-12 on quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study
    Kita, M.
    Fox, R. J.
    Phillips, J. T.
    Hutchinson, M.
    Havrdova, E.
    Sarda, S. P.
    Kong, J.
    Viglietta, V.
    Sheikh, S. I.
    Dawson, K. T.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 254 - 254
  • [36] Clinical efficacy of BG-12 (dimethyl fumarate) for relapsing remitting multiple sclerosis according to prior therapy: an integrated analysis of the phase 3 DEFINE and CONFIRM studies
    Hutchinson, M.
    Gold, R.
    Fox, R. J.
    Havrdova, E.
    Giovannoni, G.
    Zhang, A.
    Hotermans, C.
    Stephan, M.
    Bar-Or, A.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 235 - 235
  • [37] 3-Year Follow-up of Oral BG-12 (Dimethyl Fumarate) for Relapsing-Remitting Multiple Sclerosis (RRMS): Integrated Clinical Outcomes from the DEFINE, CONFIRM, and ENDORSE Studies
    Gold, R.
    Phillips, J. T.
    Bar-Or, A.
    Hutchinson, M.
    Kappos, L.
    Rana, J.
    Zhang, R.
    Yang, M.
    Viglietta, V.
    Sheikh, S. I.
    Fox, R. J.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 932 - 932
  • [38] Effects of oral BG-12 (Dimethyl Fumarate) on Magnetic Resonance Imaging (Mri) Outcomes in Relapsing-Remitting Multiple Sclerosis (Rrms): an Integrated Analysis of the Phase 3 Define and Confirm Studies
    Bar-Or, A.
    Arnold, D. L.
    Gold, R.
    Fox, R. J.
    MacManus, D. G.
    Yousry, T.
    Kurukulasuriya, N. C.
    Zhang, R.
    Viglietta, V.
    Stephan, M.
    Dawson, K. T.
    Miller, D. H.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (12) : 1836 - 1836
  • [39] Effects of BG-12 on Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study
    agarwal, Sonalee
    Kappos, Ludwig
    Gold, Ralf
    Arnold, Douglas
    Bar-Or, Amit
    Giovannoni, Gavin
    Selmaj, Krzysztof
    Kong, Jessica
    Sheikh, Sarah
    Dawson, Katherine
    NEUROLOGY, 2012, 78
  • [40] Safety and tolerability of BG-12 in the phase 3 DEFINE trial in patients with relapsing-remitting multiple sclerosis
    Selmaj, K.
    Gold, R.
    Kappos, L.
    Bar-Or, A.
    Arnold, D.
    Giovannoni, G.
    Sweetser, M.
    Novas, M.
    Raghupathi, K.
    Dawson, K.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S451 - S451
12345